Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

536.58 -2.65

Buy Sell

Overview

Share price change

24h

Current

Min

548.38

Max

563.26

Key metrics
By Trading Economics
Income	-36M -94M
Sales	-9.7M 311M
EPS	-1.38
Profit margin	-30.318
Employees	915
EBITDA	-36M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+25.18% upside

Dividends
By Acuity
Next Earnings	30 lip 2026

Market Stats
By TradingEconomics
Market Cap	393M 12B
Previous open	539.23
Previous close	536.58

News Sentiment

By Acuity

34%

66%

87 / 340 Ranking in Healthcare

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lip 2026, 23:56 UTC

Madrigal Pharmaceuticals Inc is trading higher in after-market hours, reflecting a notable increase since Monday's close, despite no specific news identified.

20 lip 2026, 16:02 UTC

Social Media

Madrigal Pharmaceuticals is lower today amid aggressive call buying and heightened market volume, with broader inflation concerns influenced by geopolitical tensions.

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

25.18% upside

12 Months Forecast

Average 690.08 USD 25.18%

High 964 USD

Low 553 USD

Based on 13 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

87 / 340 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.